ATF4 and gastric cancer: Moreover, we found that patients with higher ATF4 expression in gastric cancer under adjuvant chemotherapy treatment have a lower progression-free survival (PFS) (hazard ratio (HR): 1.86, 1.3–2.64, log rank p = 0.00053, Figure 2C) and a lower overall survival (OS) (HR: 1.61, 1.13–2.28, log rank p = 0.0075, Figure 2D) than patients with lower ATF4 expression, suggesting that higher ATF4 expression is a poorer prognostic factor for gastric cancer patients who received adjuvant chemotherapy treatment.